To the full analysis
Sanara MedTech Stock: Growth
SMTISanara MedTech reported $103.12M in revenue for fiscal 2025, up 19% on the prior year, up 45.9% a year on average over up to five years. That makes seven years of growth in a row.
Daily figure as of 20 Nov 2026
Revenue (Annual rate)
39.3%
per year from 2006 to 2025, per share 13%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per Year by Period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 45.9% | 40.8% | 39.3% |
| Revenue per share | 34.5% | 14.2% | 13.0% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Growth Over Time
Sanara MedTech reported a loss in 19 of 20 fiscal years since 2006, most recently in 2025. In the quarter to 30 Sep 2026 revenue grew 8.0% on the prior year quarter, after an average of 13.4% in the four quarters before.
Fiscal Years at a Glance
How Revenue and Earnings Grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $189.76K | −$623.56K | −$415.4K |
| 2007 | $630.51K | −$542.76K | −$462.55K |
| 2008 | $290.18K | −$1.77M | −$1.06M |
| 2009 | $288.02K | −$2.3M | −$1.3M |
| 2010 | $910.42K | −$5.14M | −$1.28M |
| 2011 | $2.21M | −$12.74M | −$343.6K |
| 2012 | $1.17M | −$1.85M | −$1.23M |
| 2013 | $1.73M | −$4.15M | −$1.85M |
| 2014 | $2.63M | −$2.28M | −$1.69M |
| 2015 | $3.37M | −$1.34M | −$1.21M |
| 2016 | $5.51M | −$415.75K | $406.22K |
| 2017 | $6.3M | $331.31K | −$225.74K |
| 2018 | $5.84M | −$600.57K | $268.66K |
| 2019 | $11.77M | −$2.81M | −$3.87M |
| 2020 | $15.59M | −$4.36M | −$5.68M |
| 2021 | $24.14M | −$7.92M | −$5.56M |
| 2022 | $45.84M | −$7.94M | −$6.3M |
| 2023 | $64.99M | −$4.3M | −$3.51M |
| 2024 | $86.67M | −$9.66M | −$253.08K |
| 2025 | $103.12M | −$37.56M | $2.16M |
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026; valuation signal Fairly valued since 17 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
